Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib and Olaparib in KRAS G12C Mutated Advanced Solid Tumors
NCT06130254Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adagrasib in solid tumor, non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and 3 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events at 1 year and Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 1 year. Started Jan 2024; status: terminated.
02
Drugs
adagrasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic cancer (PC)breast cancerovarian cancer
Beyond the preview
Go deeper on NCT06130254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130254.